Arkolith/Insider Trading/LENZ/Form 4

Chevallard Daniel R.

Chief Financial OfficerLENZ Therapeutics, Inc. (LENZ) · full profile →Form 4 · filed Nov 7, 2025
Net Buying
Open-Market Buys
$50K
Open-Market Sells
$0
Net Open-Market Flow
$50K
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Nov 7, 2025Buy(P)2K$22.76$50K5K
Nov 7, 2025Buy(P)20$22.71$4543K

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001815776-25-000072) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML